title: Regulatory watch: The orphan drug pipeline in Europe.
authors.affiliation: KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven 3000, Belgium.
authors.forename: Thomas
authors.initials: T
authors.lastname: Morel
authors.affiliation: Federal Agency for Medicines and Health Products, Brussels 1060, Belgium.
authors.forename: André
authors.initials: A
authors.lastname: Lhoir
authors.affiliation: KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven 3000, Belgium.
authors.forename: Eline
authors.initials: E
authors.lastname: Picavet
authors.affiliation: European Medicines Agency, London E14 5EU, UK.
authors.forename: Segundo
authors.initials: S
authors.lastname: Mariz
authors.affiliation: Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal.
authors.forename: Bruno
authors.initials: B
authors.lastname: Sepodes
authors.affiliation: European Medicines Agency, London E14 5EU, UK.
authors.forename: Jordi
authors.initials: J
authors.lastname: Llinares
authors.affiliation: Department of Hepatology and Metabolic Centre, University Hospitals Leuven, Leuven 3000, Belgium.
authors.forename: David
authors.initials: D
authors.lastname: Cassiman
mesh_terms: D005060:Europe; D006801:Humans; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence*; D035583:Rare Diseases / Q000188:drug therapy*